Incidence of metallo-betalactamase producing pseudomonas aeruginosa in Kesar SAL Medical College and Hospital, Ahmedabad

Abstract

Metallo-betalactamase producing pseudomonas aeruginosa have been reported to show resistance to carbepenem drugs. Detection of metallo-betalactamases producing pseudomonas is now important to prevent their spread as dissemination of these bacteria could be fatal to the patients. The present study was undertaken over period of six months from November-2010 to May-2011 in Kesar SAL Medical College & Research institute, Ahmedabad to study the incidence of MBL producing pseudomonas aeruginosa from various clinical specimens. 100 isolates were obtained from different clinical samples of patients. These isolates were subjected to susceptibility testing to antipseudomonal drugs as per CLSI guidelines they were further screened for production of MBL by two methods i.e. EDTA impregnated imipenem double disc synergy method and Imipenem -EDTA combined disc test.. Out of hundred isolates 55 imipenem resistant isolates were screened for MBL production. 38 isolates showed MBL production. MBL production was found to be 9.09%. This presents therapeutic challenge to the clinicians and also needs proper selection of antibiotics especially carbapenems.

Incidence of carbapenem-resistant pseudomonas aeruginosa in clinical samples

“…[1][2][3] The carbapenemes have been drug of choice for the treatment of serious infection caused by gram negative bacterial infections. [4] Pseudomonas shows resistance to carbapenem due to decrease outer membrane permeability, increased efflux system, alteration penicillin binding protiens and carbapenem hydrolyzing enzymes carbapenemase. [5] The introduction of carbapenem, of great help to the clinician for the treatment of serious bacterial infections caused by beta lactam resistant bacteria, Carbapenem, due to their stability to hydrolysis by the most beta lactamase, have been the drug of choice for treatment of infection caused by penicillin resistant or carbapenem resistant gram negative infections.…”